In tumor xenografts, sorafenib has demonstrated preclinical activity in several advanced solid tumor models harboring oncogenic b-raf or K-ras mutations or increased signaling through Raf due to upstream receptor tyrosine kinase overexpression (3–5). The gene discussed is RAF1; the disease is neoplasm.